|Articles|May 15, 2017
- BioPharm International-05-15-2017
- Volume 2017 eBook
- Issue 1
Gearing Up for Biosimilars
Author(s)Tim Sturgeon
Contract manufacturers prepare for anticipated biosimilars manufacturing demands through expansion and acquisition.
Advertisement
Compared to traditional small-molecule generics, the R&D costs and development times for biosimilars are significantly greater. With demand for services in the biosimilars space set to soar, many contract development and manufacturing organizations are increasing their capabilities in this field. Expansions including in-house development, partnerships and joint ventures, or bolt-on acquisitions are summarized.
Download BioPharm International's
.
Articles in this issue
over 8 years ago
Customer Relationship Management in Contract Manufacturingover 8 years ago
Getting Biopharmaceutical Tech Transfer Right the First Timeover 8 years ago
CMOs Tackle New Challengesover 8 years ago
Insourcing vs Outsourcing: Choosing the Right Strategyover 8 years ago
Operations and Quality Oversight of CMOsover 8 years ago
Quality Metrics and CMO AgreementNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
4
$1.8M RedHill Deal Highlights Growing Worldwide Focus on H. pylori Treatment Access
5
